Related Experiment Video

Updated: Mar 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy

Isabelle K Vila1, Yixin Yao1, Goeun Kim2

  • 1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancer Cell
|February 7, 2017
PubMed

Insights

Loss of UBE2O protein significantly impairs tumor initiation, growth, and metastasis by affecting cellular metabolism. Targeting the UBE2O-AMPKα2 pathway offers a potential new strategy for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The UBE2O gene is located at the 17q25 locus, frequently amplified in human cancers.
  • The specific role of UBE2O in cancer development and progression was previously undefined.

Purpose of the Study:

  • To investigate the role of UBE2O in tumor initiation, growth, and metastasis.
  • To elucidate the molecular mechanisms underlying UBE2O's function in tumorigenesis.
  • To evaluate UBE2O as a potential therapeutic target for cancer.

Main Methods:

  • Utilized MMTV-PyVT and TRAMP mouse models for tumor studies.
  • Assessed the impact of Ube2o deletion on tumor development and metabolic reprogramming.
  • Investigated the interaction between UBE2O, AMPKα2, mTOR, and HIF1α pathways.
  • Employed pharmacological inhibition of UBE2O in preclinical cancer models.

Main Results:

  • Ube2o deletion in mice significantly inhibited tumor initiation, growth, and metastasis.
  • UBE2O was found to target AMPKα2 for ubiquitination and degradation, promoting mTOR-HIF1α pathway activation.
  • Inactivation of AMPKα2, but not AMPKα1, reversed the tumor-suppressive effects of UBE2O loss.
  • Pharmacological blockade of UBE2O effectively inhibited tumorigenesis by restoring AMPKα2 levels.

Conclusions:

  • The UBE2O-AMPKα2 signaling axis plays a critical role in promoting cancer progression.
  • Targeting UBE2O represents a promising therapeutic strategy for inhibiting tumor growth and metastasis.
Keywords:
AMPKAMPKα2HIF1αUBE2Oarsenitebreast cancercancer metabolismmTORprostate cancerubiquitination

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K